Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This project is an open, dose escalation and expansion phase I clinical study. The first
phase is a dose escalation study, and the second phase is a dose expansion study based on the
Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase.
The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in
hematological tumor subjects.